Verve Therapeutics is a publicly listed company tracked for investment-relevant business developments.
Verve-102's single infusion permanently knocks down PCSK9, cutting LDL 62% for 18+ months; combines CRISPR base editing with mRNA delivery to effectively cure atherosclerotic cardiovascular disease.